Cargando…

Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis

BACKGROUND: To compare the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and solvent-based taxanes (sb-taxanes) as neoadjuvant therapy in the treatment of breast cancer. METHODS: We systematically searched the PubMed, Embase, and Cochrane Central Register databases. R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Miao, Liu, Siyao, Yang, Liu, Wang, Shu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863369/ https://www.ncbi.nlm.nih.gov/pubmed/33541289 http://dx.doi.org/10.1186/s12885-021-07831-7

Ejemplares similares

Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis
por: Li, Yong, et al.
Publicado: (2020)

Neoadjuvant nab-paclitaxel in the treatment of breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2016)

Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions
por: Maurer, Kathryn, et al.
Publicado: (2017)

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
por: Yang, Yafan, et al.
Publicado: (2023)

Enhanced Efficacy of Neoadjuvant Chemotherapy with Nab-Paclitaxel and Platinum for Locally Advanced Cervical Cancer
por: Yu, Xiao-Li, et al.
Publicado: (2021)

Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis
por: Lee, Hwaryeon, et al.
Publicado: (2020)

nab-Paclitaxel dose and schedule in breast cancer
por: Martín, Miguel
Publicado: (2015)

A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer
por: Lu, Haili, et al.
Publicado: (2021)

Nab-paclitaxel-associated photosensitivity: report in a woman with non-small cell lung cancer and review of taxane-related photodermatoses
por: Beutler, Bryce D., et al.
Publicado: (2015)

Differences in Fatty Acid Oxidation between Nab-Paclitaxel- and Solvent-Based Paclitaxel-Treated A549 Cells Based on Metabolomics
por: Huang, Jhih-Wei, et al.
Publicado: (2021)

Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials
por: Liu, Yun, et al.
Publicado: (2017)

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2016)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel
por: Chen, Nianhang, et al.
Publicado: (2014)

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
por: Palumbo, Raffaella, et al.
Publicado: (2015)

Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
por: Liu, Yin, et al.
Publicado: (2022)

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer
por: Huang, Liang, et al.
Publicado: (2015)

Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy
por: Tong, Yi Tat, et al.
Publicado: (2023)

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
por: Munster, Pamela N., et al.
Publicado: (2022)

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective
por: Dranitsaris, George, et al.
Publicado: (2015)

Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
por: Wang, Chengzheng, et al.
Publicado: (2023)

Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis
por: Damm, Marko, et al.
Publicado: (2021)

Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: He, Fei, et al.
Publicado: (2021)

Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
por: Yamamoto, Yutaka, et al.
Publicado: (2011)

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer
por: Vishnu, Prakash, et al.
Publicado: (2011)

nab-Paclitaxel for the treatment of pancreatic cancer
por: Kim, George
Publicado: (2017)

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
por: Kokubu, Hiraku, et al.
Publicado: (2023)

Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma
por: Fan, Yun, et al.
Publicado: (2016)

Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial
por: Kin, Takanori, et al.
Publicado: (2020)

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2022)

Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
por: Xie, Yifan, et al.
Publicado: (2021)

Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel
por: Huang, Jhih-Wei, et al.
Publicado: (2021)

A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer
por: Okano, Naohiro, et al.
Publicado: (2022)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
por: Wan, Rui, et al.
Publicado: (2023)

nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings
por: Brufsky, Adam
Publicado: (2017)

Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer: Retrospective single-institution observational study
por: Sugiyama, Keiji, et al.
Publicado: (2019)

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel()
por: de Leon, Maria C.B., et al.
Publicado: (2013)

The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy
por: Nakazawa, Yuko, et al.
Publicado: (2020)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_74ojdu3abo9benkuif31dpihdi